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ABSTRACT

ARTICLE HISTORY

Introduction: Chagas disease (CD) is one of the most neglected public health problems in the
Americas, where <1% of the estimated 6 million people with the infection have been diagnosed and
treated. The goal of treatment is to eliminate the parasite, decrease the probability of cardiomyopathy
and other complications during the chronic stage of infection, and interrupt the cycle of disease
transmission by preventing congenital infection. Currently, only benznidazole (BZN) and nifurtimox
are recognized by the World Health Organization as effective drugs for treatment of CD. In this paper,
we provide an overview of the clinical pharmacology of BZN.
Areas covered: This review covers the historical background, chemistry, mechanism of action, pharmacokinetics, preclinical research, resistance, clinical research, toxicology, adverse effects, and current
regulatory status of BZN.
Expert commentary: Ongoing investigations aim to optimize BZN therapy by adjusting the current
standard regimen or by combining BZN with new chemical entities. These studies are assessing
alternatives that improve safety while maintaining or increasing the efficacy of BZN. Timely diagnosis
and antitrypanosomal treatment are critical components of programs to eliminate CD as a public health
problem, and can dramatically reduce the heavy burden of morbidity and mortality caused by the
disease.
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1. Introduction
Chagas disease (CD) is one of the most neglected public
health problems in the Americas, where <1% of the estimated
6 million cases (including >300,000 in the United States) [1,2]
have been diagnosed and treated. CD is also a significant
public health challenge in Europe, where <10% of the estimated 68,000–122,000 cases have been diagnosed or treated
[3]. Globally, CD creates an annual burden exceeding 800,000
disability adjusted life years and $600,000,000 in healthcare
costs [4].
Caused by the protozoan Trypanosoma cruzi, CD is mainly
spread by triatomine bugs and by mother-to-child transmission. The parasite is also transmitted through blood transfusions, organ donations, laboratory accidents, needle sharing
among drug users, or orally through food and drink contaminated with triatomines or their feces [5].
CD begins with an acute phase with a lack of defining features;
it is often asymptomatic or resembles a common viral illness,
although more serious outcomes such as myocarditis or meningoencephalitis are possible. During this time, T. cruzi trypomastigotes are directly observed in the bloodstream. After this comes
an indeterminate chronic phase during which T. cruzi lodges in
organ tissue in amastigote form, inducing a specific immune
response. Although most remain asymptomatic, 30–40% of
patients progress to an advanced disease stage, usually years to
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decades after the initial infection. The advanced chronic phase
frequently involves damage to the heart’s conduction system and
myocardium, which can result in heart failure and sudden death.
In the Americas, myocarditis secondary to CD is the most common form of nonischemic cardiomyopathy [6]. In other cases, CD
produces gastrointestinal complications (especially megaesophagus and megacolon), or disorders of the central or peripheral
nervous system, particularly in immunocompromised patients.
Benznidazole (BZN) and nifurtimox (NFX) are the only drugs with
proven effectiveness against T. cruzi. Both drugs are over 40 years
old; NFX, developed by Bayer, was registered in 1967 and Roche
registered benznidazole in 1971. The goal of etiological treatment of CD with BZN or NFX is to eliminate the parasite, thereby
improving clinical outcomes in the patient and interrupting the
cycle of disease transmission by blocking the congenital route of
infection [7].
Treatment recommendations have historically varied depending on disease phase and patient age. Two important shifts have
occurred. Based on clinical trials in the late 1960s, investigators
affirmed that NFX and BZN were effective for treating both acute
and chronic CD [8]. However, in 1983 an expert panel recommended against treatment in the chronic phase, based on the
limited evidence of efficacy available and the belief that chronic
CD symptoms were the product of an intense immune response
unrelated to parasite presence, rendering etiological treatment
fruitless [9]. Subsequently, although acute or congenital cases
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and children were routinely treated, adults in the chronic phase
(the vast majority of CD patients) could only hope for palliative
care. Nonetheless, by the late 2000s, evidence mounted indicating that parasite persistence acted as a trigger for chronic CD
pathology [10]. Key studies demonstrated that etiological treatment significantly improved clinical outcomes in adults with
chronic CD [11–13]. The indication for supporting treatment
during the chronic phase of infection was finally reinstated, and
the World Health Organization (WHO), Centers for Disease
Control (CDC), Médecins sans Frontières/Doctors without
Borders (MSF), and other health organizations, as well as national
guidelines in endemic and non-endemic countries, recommended offering treatment to adults during the chronic indeterminate phase.
Currently, etiological treatment of CD using BZN and nifurtimox is indicated for the following: (a) the acute phase,
including neonates or infants with congenital transmission;
(b) reactivation of infection due to immune suppression; (c)
the chronic phase in patients up to 18 years old, and (d)
women of childbearing age with T. cruzi infection (contraception is recommended during treatment). Treatment may also
be considered as a prophylactic measure for patients who are
about to receive immunosuppressive therapy; however, there
is not a complete consensus among experts on this recommendation, as some prefer to monitor patients closely and
only treat in the event of reactivation.
There is agreement in international clinical guidelines that
antiparasitic treatment should be offered to adults aged
19–50 years without advanced Chagas heart disease, and is
optional for those older than 50 [14–17]. Nonetheless, such
treatment has not been widely implemented due to a host of
barriers, including the following: (1) low provider awareness of
CD and its treatment options, (2) concerns about side effects,
(3) low access to healthcare for many patients with CD, (4) lack
of a straightforward test of cure, and (5) regulatory barriers
[18–20].
BZN is the most commonly used treatment for CD. The
recommended treatment course is 5–7 mg/kg orally, divided
into two or three daily doses for 60 days for adults, and
5–10 mg/kg orally, divided into two or three daily doses for
60 days for children up to 12 [16]. In this article, we provide an
overview of the clinical and pharmacological properties of
benznidazole.

potential of nitroheterocyclic compounds as antiparasitic
agents for treating human African trypanosomiasis and CD
[23]. Although nitrofurazone did not provide optimal efficacy
and safety in humans, this earlier investigation led to the
identification and development of BZN and NFX, both
nitroaromatic compounds, for treatment of CD [23–27].

2.2. Chemistry
BZN (Box 1) is a 2-nitroimidazole derivative whose chemical
name is N-benzyl-2-(2-nitro-1H-imidazol-1-yl) acetamide. Its
molecular formula is C12H12N4O3, with a molecular weight of
260.25 g/mol. BZN is provided in different tablet sizes containing the active pharmaceutical ingredient, formulated with
common excipients approved by regulatory agencies for
human drug products.

2.3. Mechanism of action
BZN is a prodrug that exerts trypanocidal activity after activation to produce reactive metabolites [24,25,28,29]. In T. cruzi,
BZN is enzymatically activated by trypanosomal type I nitroreductases (NTR), a class of oxygen-insensitive enzymes present
in several protozoan parasites, for which there is no mammalian homologue [24].
In a series of reactions (see Patterson et al. 2014 for
detailed information), Nicotinamide adenine dinucleotide
(NADH)-dependent type I NTRs catalyze the reduction of
the 2-nitroimidazole motif to a hydroxylamine, via a nitroso
intermediate, in a two-step/two-electron transfer reaction
[24,25]. This hydroxylamine is subsequently converted, via a
series of non-enzymatic transformations, until the release of
dialdehyde glyoxal, a highly reactive metabolite capable of
forming adducts with proteins, DNA/RNA, and small molecules such as glutathione. These reactive metabolites are
toxic, resulting in a rapid and localized trypanocidal effect
against both intra- and extracellular forms of the parasite [28].

Box 1. Drug summary.
Antiparasitic class
Structural formula

Nitroimidazole derivative

Molecular formula
Molecular weight
Mechanism of
action

C12H12N4O3
260.25 g/mol
After activation by trypanosomal nitroreductases, the
reactive metabolites formed interact with several
biomolecules leading to the killing of parasites
LAFEPE, ELEA, CHEMO RESEARCH
August 29, 2017
Acute and chronic phase with some limitations
60 days
Oral

2. Introduction to benznidazole (BZN)
2.1. Historical background
BZN is a member of a large group of nitroheterocyclic compounds, which comprises molecules containing one or more
nitro-groups linked to an aromatic ring [21]. Nitroheterocyclic
compounds have a long history of human and veterinary use
as antimicrobial and antiparasitic agents. Although the particular use of nitrofuran derivatives was discontinued in some
parts of the world due to mutagenic potential, there has been
a resurgence of R&D on nitroaromatic compounds as potential
therapeutic candidates [21–25].
The identification in the 1950s of nitrofurazone as an active
compound against Trypanosoma species pointed to the

Manufacturers
US FDA approval
Indication
Treatment course
Route of
administration
Dosage form
Breastfeeding
women

Tablets – 100, 50, 12.5 mg
Not recommended; however, preliminary research
suggests that there is no risk to infants [116]
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However, glyoxal production is not likely to be the sole
cytotoxic mechanism for BZN. A recent study, employing
metabolomics approaches, showed that BZN is extensively
metabolized to a number of reactive metabolites in epimastigotes, but the authors were unable to detect glyoxal and
related adducts [30]. Instead, they proposed that covalent
binding of multiple reactive metabolites to low molecular
weight thiols (important within glutathione and trypanothione
pathways) is BZN’s primary mode of action against T. cruzi [30].
Other studies suggest BZN possesses immunomodulatory
effects in vitro, in vivo, and ex vivo, which could play an
important role in CD pathogenesis in humans [31,32].

2.4. Pharmacokinetics
The non-clinical pharmacokinetics (PK) of BZN have been
evaluated in multiple studies [33–36]. Overall findings suggest
that BZN is almost fully bioavailable when administered orally,
with a plasma half-life of 2–2.5 h, and plasma protein binding
approximating 50% across species. After absorption, BZN distributes widely to tissues, including placental and fetal tissue,
at levels similar to that in circulating blood. The metabolic and
excretion pathways for this drug have not yet been fully
elucidated (although nitroreductases are involved in the conversion of the nitroimidazole motif), but studies demonstrate
minimal metabolism in hepatic microsomes and hepatocytes
of different species, and no human-specific metabolites
[33,36]. No inhibition or induction of CYP450 enzymes at
clinically relevant concentrations were detected during in
vitro studies using human hepatocytes, although BZN was
shown to be a substrate and to increase the expression of
glycoprotein-P (efflux pump) [36,37], and to inhibit the OAT3
receptor (with possible implications for drug–drug interactions) [36].

2.5. Preclinical research
Preclinical research has yielded further insight on the susceptibility of different T. cruzi strains to BZN. Notable studies are
briefly described below.

2.5.1. In vitro studies
In vitro activity of BZN has been evaluated against >50 laboratory strains and clinical isolates of T. cruzi belonging to different discrete typing units (DTUs) [36,38–43]. A wide variety of
experimental designs has been applied to the screening process, including different stages of the parasite, axenic or intracellular parasite cultures, varying duration of treatment, and
different endpoints to measure activity. Limited interlaboratory comparability and lack of understanding of the clinical
relevance of in vitro sensitivity testing are major drawbacks for
CD drug discovery. Improved and evolving experimental
designs are paramount to answering relevant questions and
to helping translate experimental data into knowledge [44].
Overall in vitro data suggest that susceptibility of different
strains to BZN fluctuates, but the 50% inhibitory concentration
(IC50) values are always ≤19.5 μg/mL (75 μM) and vary within a
factor of 10-fold within the same assay. Activity against different
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forms of the parasite (epimastigotes, trypomastigotes, or amastigotes) also appears to vary within a relatively small range
[36,41,43]. Additionally, time-kill studies indicate that BZN’s
trypanocidal effect is both time- and concentration dependent
[38,41,43]. Using multiple strains and a high-throughput screening platform, Moraes et al. demonstrated that BZN has a rapid
trypanocidal effect and reaches 100% parasite clearance against
multiple divergent T. cruzi genotypes,41 a rate superior to that
for ergosterol biosynthesis inhibitors, for example.

2.5.2. In vivo studies
Several in vivo models mimic different aspects of human CD,
and various formats have been widely used by the scientific
community. However, current animal models have limitations,
including variability of pathogen/host interactions, spontaneous clearance of parasites, and difficulties in identifying
sterile parasitological cure and/or measuring drug treatment
in real time, and thus have limited predictive value for development of new drug candidates [45].
In vivo activity of BZN has been evaluated, in both acute
and chronic stages, against approximately 64 strains/clones
infecting (most frequently) mice, rabbits, and dogs
[36,38,39,41,46–51]. Findings in animals suggest that BZN
treatment is beneficial in both CD stages, but more efficacious
in acute models of T. cruzi infection. BZN improves survival,
decreases parasitaemia in blood and reservoir tissues including the heart and gastrointestinal tract, eventually achieving
full parasite clearance, and reduces the immunological
response to parasite antigens. In animal models, the prevention of severe chronic features of the disease is still a matter of
debate [36,50,51].
In dogs, an important reservoir of T. cruzi parasites providing an animal model where clinical findings and immunopathogenic mechanisms are similar to those reported in
humans with CD, BZN was effective in reducing parasitic
load during the acute or chronic phase of infection.
However, while BZN effectively reduced systolic cardiac function alterations, it did not prevent development of cardiomyopathy in the chronic phase [50,52–54].
Intriguingly, two recent studies suggested that BZN more
readily cures chronic infections in mice, challenging the convention that it is more efficacious during the acute stage
[55,56]. The investigators used a highly sensitive bioluminescence imaging system coupled with cyclophosphamidemediated immunosuppression (to enhance the reactivation
of any residual infection) for systematic and comparative studies of drug efficacy in vivo and ex vivo. Daily treatment of
chronically infected mice with 100 mg/kg of BZN for 5, 10, or
20 days resulted in sterile cure. However, mice in the acute
stage with the same treatment regimen for 5 or 10 days were
not cured [56]. These findings could have major implications
for new research directions.

2.5.3. Safety, pharmacology, and toxicology
Non-clinical pharmacological and toxicological profiling of BZN
has yielded multiple clinically relevant findings. Potential concerns include carcinogenicity, teratogenicity, effects on male
fertility and female pregnancy, and in vitro and in vivo genotoxicity (positive mutagenicity and clastogenicity) [34,36,47,57,58].
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These results align with findings for other nitroimidazolic drugs
used in the clinic, such as metronidazole. These toxic effects may
be partially driven by reactive oxygen species arising from the
reduction of the nitro group to an amino group by type II NTRs
(oxygen-sensitive), which are present in mammalian organisms
[24,30,36].

2.6. Resistance
Several in vitro and in vivo studies suggest, via a comparison of
parasite growth kinetics and cure rates in animal models,
evaluation of shifts in IC50 values, and molecular approaches,
that there is the potential for development of resistance to
BZN [36,59–62]. However, while there is clear evidence of
resistance in T. cruzi under multiple experimental conditions,
a direct link between in vitro/in vivo susceptibility and the
clinical efficacy of BZN is still undefined.
The mechanism of generation of resistance is likely to be
multifactorial, involving higher activity of efflux pumps, and
mutation and/or modulation of parasite gene expression
[34,36,59–62]. A recent whole genome sequencing study
showed that mutagenic effects of BZN-reactive metabolites,
combined with deficiencies in DNA repair mechanisms, could
generate early-stage, extensive alterations in the T. cruzi genome, leading to the development of BZN resistance and other
phenotypic changes [63].

3. Clinical research on benznidazole
Clinical R&D for benznidazole (and CD more generally) has been
hampered by a lack of investment. Only one large-scale, multicentric, randomized trial has taken place in the last half century
[64]. Another challenge involves the difficulty of measuring
treatment success during the chronic phase. Detection of the
parasite (or parasite DNA) is a probable indication of treatment
failure. Early studies relied on xenodiagnosis, while more
recently polymerase chain reaction (PCR) has been employed.
Negative serology is an effective proxy for parasitological cure in
acute, congenital, and early chronic cases. However, in adult
patients with chronic CD, it can take over 20 years following
treatment to revert to negative serology [12]. There is an urgent
need for development of a reliable test of cure to advance
research and facilitate treatment.

3.1. Phase I studies
In the 1970s, multiple case series supported the safety of BZN
[65–67].
Raaflaub et al. published the first study of BZN resembling a
modern Phase I study [68]. In this Roche-sponsored study,
BZN’s PK was evaluated in six healthy adult female volunteers
aged 22–24 years old, after administration of a single 100 mg
BZN dose. The investigators reported quick absorption of the
drug (Tmax 3 h), good distribution to tissues (volume of distribution 560 mL/kg) and moderately slow elimination (estimated average half-life of 12 h). No significant adverse events
were observed. Despite the small sample, the investigators
decided to proceed with a repeated-dose study (comparable

to a modern Phase II study) of 14 patients with chronic CD, in
which no adverse events were detected [69].
Perhaps the most complete Phase I research to date
assessed BZN for treatment of central nervous system cancers in adults (as an adjuvant therapy for CCNU) [70,71].
These studies, which enrolled a higher number of patients
and exposed them to incremental BZN doses (up to 40 mg/
kg, over four times higher than the doses for CD), yielded PK
and safety results compatible with prior research [68,69].
Through biopsies, the investigators confirmed high tissue
penetration of BZN, even in the central nervous system
(CNS), an observation that later became relevant when treating reactivated CNS T. cruzi infections in immunosuppressed
patients [72].
A recent Phase I, open-label, nonrandomized pharmacokinetic study with eight healthy adult volunteers investigated
the PK of a single 100 mg dose of BZN and used the calculated non-compartmental PK parameters to simulate two
multiple-dose administration regimens: 100 mg administered
every 8 h and 150 mg administered every 12 h. Observed PK
parameters were similar to those in other studies, but the
authors concluded that both simulated regimens reached
steady-state concentrations above the minimum experimental therapeutic dose. Men had lower median Cmax and
higher median volume of distribution than women, but the
limited number of individuals (N = 4 per group) precludes
definitive conclusions on the influence of sex on BZN PK [73].
The BZN label mentions that food does not seem to affect
absorption of the medication, according to comparative
bioavailability studies performed for registration of the product in the USA [36].
Studies in children and lactating women have also been
conducted. Early pediatric studies highlighted BZN’s efficacy
for treating CD, measured by persistent decreases in conventional antibody titers and seroreversion, compared to placebo,
and noted a low frequency of adverse events in children
[74,75]. Similarly, a case series and two prospective population
pharmacokinetics studies confirmed BZN’s efficacy in infants
and children using quantitative PCR (qPCR), which became
universally negative after treatment, and conventional serological tests [76,77]. The frequency of adverse events was low,
significantly below that reported for adults. Both studies
showed a significantly shorter half-life due to higher clearance
rates for BZN in younger children and infants, which was
inversely proportional to body size. A systematic literature
review with a Bayesian meta-analysis of basic pharmacokinetic
properties of BZN showed consistency across studies; the
authors provided improved estimates of the pharmacokinetic
parameters under fasting conditions for a single 100 mg dose
of BZN in adults. AUC and Cmax were 51.31 mg h/L (95%
credible interval [CrI], 45.01–60.28 mg h/L) and 2.19 mg/L
(95% CrI, 2.06, −2.33 mg/L) [78].

4. Phase II studies
In an early study of 73 patients with acute CD treated with
BZN, the cure rate (measured by xenodiagnosis) reached 88%.
Additionally, three dosing regimens were tested in 33 patients
with chronic infection: (a) 7–10 mg/kg/day for 60 days; (b) 7–
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10 mg/kg/day for 30 days; and (c) 4–5 mg/kg/day for 30 days.
There were no statistical differences between treatment efficacy, with >90% of xenodiagnoses negative, but the higher
dose produced more side effects [8].
After decades of limited research, several recent studies
have evaluated the safety and efficacy of BZN at lower,
shorter, and/or intermittent dosing regimens, both as a monotherapy and in combination with other compounds.

4.1. E1224
The E1224 study, sponsored by the Drugs for Neglected
Diseases initiative (DNDi) was a proof-of-concept, doubleblinded, randomized Phase II clinical trial [79]. E1224 (fosravuconazole), developed by Eisai, Ltd., had demonstrated
promising activity against T. cruzi in animal models [53].
Adult Bolivian patients (n = 231) with confirmed chronic
indeterminate CD were randomly assigned to five oral treatment groups: high-dose E1224 (8 weeks, total dose
4,000 mg), low-dose E1224 (8 weeks, 2,000 mg), short-dose
E1224 (4 weeks E1224 + 4 weeks placebo, 2,400 mg), BZN
standard dose (60 days, 5 mg/kg per day), or placebo
(8 weeks, E1224-matched tablets). The primary endpoint
was parasite clearance. Although E1224 initially proved capable of eliminating the parasite, the effect was not sustained at 12-months follow-up. However, 82% of patients
treated with BZN had negative PCR results at 12 months
follow-up, underscoring the drug’s efficacy. The study
served as a springboard for a currently ongoing DNDi-supported study of BZN at alternative dosing regimens and in
combination with E1224 [80].
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4.4. Intermittent regimen
A recent observational study assessed an intermittent dosage
scheme of BZN at 5 mg/kg/day in two daily doses every
5 days for a total of 60 days. One patient showed detectable
PCR at the end of treatment (1/17), corresponding to 6%
treatment failure, compared with 11/17 (65%) patients pretreatment (P = 0.01). Adverse effects were present in 10/20
(50%) patients, but in only one case was treatment suspended [83].

4.5. Ongoing studies
The aforementioned studies supported the effectiveness of
BZN for eliminating the parasite during the chronic phase of
CD, whereas E1224 and posaconazole demonstrated temporary but unsustained parasite-clearing potential. Consequently,
new research is focusing on improved regimens of benznidazole, either as a monotherapy or in combination with E1224.
These studies aim to ascertain whether the side-effect profile
might be improved while maintaining or even improving the
efficacy of the current standard dosing regimen.
Currently, two new proof-of-concept studies are underway.
BENDITA (BEnznidazole New Doses Improved Treatment and
Associations) is a Phase II randomized, multi-center study in
Bolivia assessing benznidazole at shorter or intermittent dosing regimens and in combination with E1224, compared to
placebo, in patients with chronic CD (ClinicalTrials.gov
Identifier: NCT03378661). MULTIBENZ (Evaluation of Different
Benznidazole Regimens for the Treatment of Chronic Chagas
Disease) (BERENICE Project, ClinicalTrials.gov Identifier:
NCT03191162) is testing a modified regimen of BZN for treatment of CD in the chronic phase compared to the standard
scheme [73].

4.2. CHAGASAZOL
Undertaken in Barcelona, Spain, CHAGASAZOL was a multicenter, randomized, open-label clinical trial assessing two
schedules of posaconazole (100 mg/12 h and 400 mg/12 h
for 60 days), compared to BZN (5 mg/kg/day for 60 days) in 78
chronic CD patients [81]. During follow-up, a greater proportion of patients treated with posaconazole (81–92% vs. 38%
for BZN) had treatment failure, as measured by positive realtime PCR for T. cruzi in peripheral blood.

4.3. STOP CHAGAS
STOP CHAGAS assessed posaconazole and BZN as monotherapies, posaconazole in combination with BZN, and placebo in a
sample of 120 subjects from four Latin American countries and
Spain [82]. After 180 days of follow-up, only 13.3% of patients
treated with posaconazole had negative PCR results, compared with 10% in the placebo arm. However, 80% of patients
in the BZN+posaconazole group and 86.7% of patients who
received BZN as a monotherapy had negative results. Similar
to E1224, posaconazole showed some effectiveness during
treatment, but negativization was not sustained in the follow-up period.

4.6. Phase III studies
Phase III studies have evaluated BZN’s efficacy in eliminating
the parasite and improving clinical outcomes. Antiparasitic
effects of treatment are measured through detection of antibodies, parasites, and/or parasite DNA. Success of treatment is
gauged by negative serology, while therapeutic failure is
demonstrated by parasite detection. However, the reliability
of these indicators hinges on the following: (a) the age of the
patient at the moment he/she received the treatment; (b) the
time elapsed between treatment and follow-up; and (c) the
region where the patient was infected [7].
Reversion to negative serology is much easier to demonstrate in patients who were more recently infected.
Consequently, the efficacy of BZN for treatment of patients
in the acute phase due to vector transmission or congenital
infection has been clearly shown in several observational studies with a cure rate of consistently over 80% [66,84–88].
Studies assessing the efficacy of BZN in chronically infected
patients are summarized in Table 1. BZN efficacy in asymptomatic chronically infected children was demonstrated by two
double-blinded, placebo-controlled trials in the 1990s. Cure
rates, defined as conversion from positive to negative serology
3–4 years after treatment, were approximately 60% [74,75]. In

Country
Argentina

Chile

Argentina

Argentina

Brazil

Argentina

Brazil

Paraguay

Brazil

Argentina

Argentina

Argentina

Brazil

Brazil

Brazil

Argentina

Argentina

Argentina

Brazil

Argentina

Brazil

Paraguay

Brazil

Argentina

Source (first author, year)
Cerisola 1971

Shenone 1981

Vigliano 1989

Gallerano 1990

de Oliveira, 1990

Viotti 1994

de Andrade 1996

Maldonado 1995

Coura 1997

Sosa-Estani 1998

Fabbro 2000

Gallerano 2000

Silveira 2000

Britto 2001

Cançado 2002

Sosa-Estani 2002

Altcheh 2003

Schijman 2003

Diniz-Marques 2003

Streiger 2004

Meira 2004

Vera de Bilbao 2004

de Andrade 2004

Viotti 2006

Obaservational
N: 153

Observational
N: 13
Observational
N: 30
Cohort
N: 48
Observational
N: 49 (64 en RS PlosOne)
Cohort
N: 31
Cohort
N: 12
Clinical trial
N: 58

5 mg/kg/d) for 60 days

N: 59

Adults

Children

Children

Adults

Children

Children

Children

Children

10–14 years old

5 mg/kg/d for 60 days

14.0

4.0

1.0

0.5

3.0

8.0

2.0

7.2

7.5 (mean)

6.9 (mean)

Length of follow-up
(years)
0.2–2.7

8–20.0

6.0
6.0

5 mg/kg/d for 30 days

2.0

2.3 (mean)

2.0

3.0

1.6 (n = 75)
5.0 (n = 8)
1.6 (n = 61)
5.0 (n = 13)
9.0 (n = 17)
1.6 (n = 11)
5.0 (n = 19)
9.0 (n = 29)
6.2 (mean) (range 2–13)

6.0–18.0

7.5 mg/kg/d. for 60 days

5–7 mg/kg/d for 60 days

5 mg/kg/d for 60 days

5mg/kg/d. for 30 days

5–10 mg/kg/d for 60 days

5–8mg/kg/d. for 60 days

5–8 mg/kg/d. for 60 days

5 mg/kg/d for 60 days

5 mg/kg/d. for 60 days

5–6 mg/kg/d for 30–60 days 20.0

5–7 mg/kg/d for 60 days

4–8 mg/kg/d for 45–60 days 5.3

5 mg/kg/d. for 30 days

5 mg/kg/d for 60 days

5 mg/kg/d. for 30 days

5–7 mg/kg/d for 60 days

7.5 mg/kg/d. for 60 days

5 mg/kg/d for 30 days

5–8 mg/kg/d for 60 days

5 mg/kg/d for 60 days

5 mg/kg/d for 35 days

8–15 mg/kg/d for 30 days

Dosage
4–10 mg/kg/d

Study design and sample size
(N)
Age group
Observational
Adults
N: 33
Cohort
Adults
N: 21
Cohort
Adults
N: 131
Clinical trial
Adults
N: 51
Cohort
Children and Adults
N: 50
Observational
Adults (>18 years
N: 110
old)
Clinical trial
Children
N: 64
Cohort
Children
N: 20
Clinical trial
Adullts
N: 50
Clinical trial
Children
N: 55
Observational
Children and adults
N: 38
Cohort
Adults
N: 130
Cohort
Children
N: 10
Cohort
Children and Adults
N: 26
Observational
9 to 69
N: 113
Observational
1–4 years old
N: 83
N: 91
5–9 years old

Table 1. Clinical studies to assess efficacy against Trypanosoma cruzi infection in chronic phase. 1971–2018.

CS-IHA, IIF- (20.9)

NCS-EIA AT 24- (84.7)

CS-IHA, IIF, EIA- (0.0)
NCS-CoML- (66.6)
CS-IIF, EIA- (0.0)

CS-DA 2ME, IHA, IIF- (59.2)

CS-IHA, EIA- (18.7)

CS-IHA, EIA- (49.3)
CS-IHA, EIA- (87.2)
CS-IHA, EIA- (33.7)
CS-IHA, EIA- (62.9)
CS-IHA, EIA- (88.2)
CS-IHA, EIA- (0.0)
CS-IHA, EIA- (52.6)
CS -IHA, EIA- (69.0)
CS-IHA, EIA- (80.0)
NCS-F 2/3 Ag- (100.0)
CS-IHA, EIA- (23.3)

CS-IHA, EIA- (7.9)

CS-IHA- (37.5)
CS-IIF, EIA- (12.5)
Not reported

CS-IHA, IIF- (0.0)

CS-IHA, IIF, EIA- (11.3)
NCS-EIA F29- (62.0)
CS-IIF- (5.3)

Not reported

CS-IHA, IIF, EIA- (0.0)
NCS-EIA AT 24- (57.8)
CS-IHA, IIF, EIA- (0.0)

CS-IHA, EIA- (35.0)

CS-FC- (49.0)
CS-HIA- (34.0)
CS-IHA, IIF- (8.0)

CS-IHA, IIF- (16.0)

CS-IHA- (0.0)

Serological test* (%
Negative)
CS (0.0)

(Continued )

PCR (39.7)
[described in Galvao et al.
2003]
XD (4.0)

XD (0.0)

PCR (33.3)

XD (0.0)

Not reported

PCR (4.2)

ND

XD (4.3)

ND

XD (12.5)
PCR (12.5)
XD (16.6)
PCR (35.4)
ND

XD (23.5)

XD (0.0)

XD (4,7)

XD (7.7)

XD (0.0)

ND

XD (4.0)

XD (40.0)

XD (27.0)

Not reported

XD (13.0)

Parasitological/molecular test**
(% Positive)
XD (6.1)
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Argentina

Argentina

Honduras
Cohort
Guatemala
N: 232
Bolivia
N: 124
N: 2449
Brazil
Cohort
N: 80
Brazil
Cohort
N: 16
Argentina
Cohort
N: 760
Argentina
Observational
N: 55

Sanchez-Negrette 2008

Sosa-Estani 2009

Yun 2009

Argentina

Spain

Brazil

Argentina

Argentina

Spain

Argentina

Argentina

Brazil

Argentina

Bolivia

Viotti 2011

Pérez Ayala 2011

Machado-de-Assis 2012

Fabbro 2013

Rumi 2013

Molina 2014

Fabbro 2014

Moscatelli 2015

Fragatta-Filho 2016

Sartor 2017

Torrico 2018

Cohort
N: 62
Cohort
N: 53
Cohort
N: 64
Cohort
N: 94
Cohort
N: 29
Cohort
N: 22
RCT
N: 26
Cohort
N: 73
Cohort
N: 14
Cohort
N: 263
Cohort
N: 66
RCT
N: 45

5 mg/kg/d for 60 days

5–7.5 mg/kg/d for 60days

5 mg/kg/d for 60 days

5 mg/kg/for 30–60 days

5mg/kg/d. for 30 days

300 mg daily for 60 days

0.8

2.0–5.0

23.0

16.9 (± 6.8)

1.0

3.0

12.0

23.0

10.4 (± 7.8)

9.0

3.0

1–3
1.5
5.0

14.0

3.8 (mean)

2.0

1.0

Length of follow-up
(years)
0.5

Adults

Children

5 mg/kg/d for 60 days

5 mg/kg/d for 60 days

Children and Adults 6.2 mg/kg/d for 30 to
60 days
Adults
5 mg/kg/d for 60 days

1.0

0.5

19.6

5.0

Children and Adults 5 mg/kg/d for 30 to 60 days 22.7

Adults

BNZ (n = 53):
5 mg/kg/d for 30 days
Adults
BNZ (n = 64):
5 mg/kg/for 30–60 days
Children and Adults 5–10 mg/kg/d for
40–60 days
Adults
5–10 mg/kg/d for
40–60 days
Children
5 mg/kg/d for 60 days

Adults

Adults

Adults

Children and Adults 5–10 mg/kg/d for
40–60 days
Adults
5 mg/kg/d for 30 days

Children and adults

Children

Children

5 mg/kg/d) for 60 days

5 mg/kg/d for 60 days

8 mg/kg/d for 60 days

Dosage
5 mg/kg/d for 60 days

CS-EIA (0.0)

Not reported

CS-IIF- (37.5)

CS-IHA, EIA- (6.7)

CS-IHA, EIA- (43.8)

CS-IHA, EIA- (11.7)
CS-IIF- (24.7)
CS-EIA- (44.8)
NCS-F29- (89.5)
CS-IHA- (0.0)
CS-EIA- (9.1)
CS-EIA- (0.0)

CS-IHA, IIF, EIA- (20.8)
NCS-Multiplex- (81.2)
CS-IIF, EIA- (0.0)

CS-IHA- (37.7)
CS-IIF- (45.5)
CS-EIA- (45.5)
CS-IIF- (4.8)

CS-EIA- (0.0)
NCS-FC-Alta IgG- (0.0)
CS-IHA, IIF, EIA- (8.8)

CS-IIF, EIA- (5.0)

CS-IHA- (5.2)
NCS-CMA-EIA- (77.7)
NCS-RAM-EIA- (0.0)
NCS-IRA-EIA-Ag 13(66.7)
CS-IHA- (62.5)
CS-IIF- (43.8)
CS-EIA- (87.5)
NCS-EIA F29- (87.5)
CS-EIA- (92.7)
CS-EIA- (58.0)
CS-EIA- (5.3)

CS-EISA- (4.5)
NCS-EIA SAPA-(31.8)
Not reported

Serological test* (%
Negative)
CS-IHA, EIA- (0.0)

PCR (18.0)

PCR (1.5)

Not reported

PCR (0.0)

Not reported

Rt-PCR (38.5)

PCR (4.8)

Not reported

PCR (44.8)

PCR (0.0)

Not reported

XD (1.6)

XD (0.0)

Not reported

PCR (87.2)

PCR (88.7)

XD (0.0)
PCR (12.5)

ND

HC (11.1)

PCR (0.0)

Parasitological/molecular test**
(% Positive)
PCR (14.3)

*CS = conventional serology (EIA, IIF, and IHA); NCS = non-conventional serology. IIF = indirect immunofluorescence; EIA = enzyme-linked immunosorbent assay; IHA = indirect hemagglutination.
**PCR = polymerase chain reaction; XD = xenodiagnoses.

Brazil

Hasslocher-Moreno, 2010

Fabbro 2010

Viotti 2009

de Lana 2009

Fernandes 2009

Brazil

de Castro 2006

Cohort
N: 16

Bolivia

Flores-Chavez 2006

Study design and sample size
(N)
Age group
Cohort
Adults
N: 14
Cohort
Children
N: 35
Cohort
Adults
N: 27
Observational
Adults
N: 18

Country
Argentina

Source (first author, year)
Lacunza 2006

Table 1. (Continued).
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one study, at 48 months follow-up, 51% of the placebo group
had a positive xenodiagnosis compared to 4.1% of patients
treated with BZN [75]. These studies supported policy change
in endemic countries toward treating children with indeterminate chronic CD.
As patient age and length of infection increase, the time
needed for seroreversion also increases. In one study, which
defined treatment success as reversion to negative serology
and treatment failure as a positive parasitological (xenodiagnosis) or molecular test (PCR), the rate of negativization was
higher in children and adolescents than in adult patients
(28.3% vs. 11.1%) in short term (<10 years) follow-up, and
substantially higher (49.6% vs. 18.2%) in long-term
(>10 years) follow-up (Figure 1(a)). Similarly, rates of treatment
failure were much lower for children/adolescents compared to
adults in both long and short-term follow-up. Timely treatment of children during the early chronic phase can yield a
cure rate of up to 80% [89,90], with higher rates observed
when long-term follow-up is performed (Figure 1(b)).
Furthermore, following treatment, antibody titer levels
decrease much more quickly in children than in adults, even
if they do not cross the cut-off to become non-reactive. A
marked decrease in antibody titers in children is apparent
three months after treatment by enzyme linked immunosorbent assay or immunofluorescence assay, and six months after
treatment using indirect haemagglutination assay [74,75].
Despite the difficulty of measuring cure in chronically
infected adults, most observational studies have demonstrated improved clinical outcomes in patients who are treated
with BZN, compared to untreated patients (Table 2). In a
sample of 566 Argentinian patients, only 4% of the treated
group experienced progression of heart disease compared to
14% in the untreated group [11]. Other studies in different
settings have described similar results, with reduction in disease progression of up to 75% [12,91–95]. However, other
researchers did not observe differences between treated and
untreated patients [96,97].
Some research indicates treatment with BZN eliminates
maternal transmission of CD. In a multicenter, observational
study of a cohort of mothers and children, trypanocidal treatment of women with CD proved effective at preventing congenital transmission of T. cruzi and halting disease progression
[92]. These results are consistent with other observational

Table 2. Comparison of studies measuring long-term clinical outcomes after
etiological treatment of chronic Chagas disease with benznidazole.

First author

Number
of
Years
treated/
of
untreated followpatients
up

Viotti 1994
Gallerano 2000
Viotti 2006
Fabbro 2007
Fabbro 2014
Morillo 2015
Fragata-Filho 2016

131/70
535/668
283/283
54/57
71/46
1431/1423
263/47

8
5
6
21
20
6
20

% with ECG
changes
treated vs.
untreated
patients

% with heart
disease
progression
treated vs.
untreated
patients

4 vs. 30
14 vs. 34
5 vs. 16
4 vs. 16
1.4 vs. 15
−
21 vs. 53

2 vs. 17
6 vs. 18
4 vs. 14
−
−
28 vs. 29
14 vs. 36

studies in which no congenital infection was detected in
children born to T. cruzi-positive mothers who were treated
before pregnancy [98–101].
A major randomized trial sought to determine whether
treatment with BZN could improve outcomes for patients who
had already developed heart disease [64]. The BENEFIT trial
(Benznidazole Evaluation for Interrupting Trypanosomiasis)
was a multicenter, double-blind, placebo-controlled trial of trypanocidal treatment of BZN in 2,854 patients with chronic CDrelated cardiomyopathy, conducted in 54 study centers in
Argentina, Bolivia, Brazil, Colombia, and El Salvador. BZN was
administered at a fixed daily dose of 300 mg for 40–80 days; the
time period was adjusted according to body weight. The primary outcome was death, implantation of a pacemaker or
defibrillator, transplant, heart failure, or other major cardiac
event. Rates of conversion to negative PCR were also measured.
After a mean follow-up of 5.4 years, there was not a significant
difference in primary outcome between the placebo and BZNtreated group, even though parasite clearance was higher in
the latter (66.2% vs. 33.5%). The mean patient age in the trial
was 55, and most patients had New York Heart Association class
I or II heart failure.
TRAENA (Treatment in Adult Patients, ClinicalTrials.gov
Identifier: NCT02386358), another randomized trial, assessed
the ability of BZN to prevent progression to chronic CD in a
sample of patients that reflected the natural distribution of the
disease (70% without demonstrable disease). The trial has
recently concluded but results have not yet been published.
Another ongoing trial, CHICAMOCHA 3, (ClinicalTrials.gov

Figure 1. (a). Percentage of patients with non-reactive serological test (cure) after treatment. Children and adult patients with short- and long-term follow-up. (b).
Percentage of patients with positive xenodiagnosis or PCR after treatment. Children and adult patients with short- and long-term follow-up.
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Identifier: NCT02369978) is evaluating both BZN and NFX
versus placebo in a sample of patients with indeterminate
CD. Both safety and parasite clearance will be assessed.
While BENEFIT, the only major clinical trial of the past
decade, showed BZN had antiparasitic effect (measured by
PCR), it was unable to demonstrate a corresponding improvement in clinical outcomes in patients treated with BZN. This
likely reflects the advanced disease stage of the patients
enrolled. In contrast, Viotti et al.’s observational study examined patients without advanced cardiomyopathy and included
a much longer follow-up period (>20 vs. 5.4 years), finding
significantly improved clinical outcomes. Therefore, the main
lesson of the BENEFIT trial is that antiparasitic treatment
should be offered as early as possible, before patients progress
to an advanced stage of CD [102].

5. Tolerability and pharmacovigilance
5.1. Adverse effects
Treatment discontinuation due to adverse events (AEs) typically ranges from 15% to 20%. AEs are more frequently
observed in adolescents and adults than infants and children [7,76,103]. Usually, treatment tolerance is satisfactory,
and patients have not demonstrated serious side effects
[7,11,91,103,104]. Although cases with severe side effects
are occasionally reported, these are generally associated
with difficulties in seeking timely medical attention or
receiving adequate care. The most commonly reported AEs
from BZN include allergic dermopathy, nausea, and vomiting. Cutaneous reactions are the most common, and are
positively associated with treatment withdrawal [105,106].
Less frequently, peripheral polyneuropathy and depression
of bone marrow have been observed. Very rarely, cases with
extensive lesions from allergic dermopathy, including
Steven Johnson Syndrome, have been reported. No new
AEs have been described in the literature in the past few
decades.
Due to AEs, oral treatments sometimes have to be discontinued. Laboratory tests have typically shown normal bilirubin
values and occasional elevation of transaminases. In all cases,
AEs disappear when the dose is diminished or treatment is
suspended. Children who underwent clinical examination
15 years after experiencing AEs did not show any pathological
signs or symptoms associated with the adverse events [107].
Several studies have attempted to identify predictors of
adverse reactions to BZN. Two studies concluded that BZN
serum concentrations are not correlated with the appearance
of serious AEs [108,109]. A Colombian study retrospectively
evaluated the safety profile of BZN in 224 adult patients to
identify factors for definitive treatment interruption and development of severe reactions [110]. A BZN dose ≥6 mg/kg/day,
adverse event severity, eosinophilia, and female sex were the
main predictors of treatment interruption.
Differences in patients’ genetic or immunological profile
could drive susceptibility to AEs. A study of adult CD patients
treated with BZN (100 mg, every 8 h, for 60 days) showed
that patients with cutaneous drug reactions had a higher
proportion of eosinophilia during treatment, and higher
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interleukin (IL)-5 and IL-10 serum concentrations at day 15
of treatment than those without cutaneous reactions [111].
Treatment interruption (secondary to moderate–severe cutaneous reactions) was more frequent in patients carrying the
HLA-B*3505 allele (45.5% vs. 15.4%, P = 0.033). No differences
in BZN serum concentrations were found. The authors concluded that the BZN cutaneous reaction rate is high (38.5%),
and related to a delayed hypersensitivity reaction with a Th2specific immune response. Additionally, the HLA-B*3505
allele could be associated with moderate–severe cutaneous
reactions.

5.2. Clinical management of adverse events
Despite the toxicological profile and documented side effects
of BZN, data from clinical studies and the extensive use of the
drug in Latin America indicate BZN can be used safely with
proper management and monitoring. In the BENEFIT trial, only
8.3% of patients had to discontinue treatment secondary to a
serious AE, despite the older mean age (55) in the sample [64].
In over 2,000 patients treated with BZN by MSF in Bolivia, only
10.2% discontinued treatment. MSF used a system of weekly
follow-up to minimize treatment suspension [106].
Treatment of CD with BZN should ideally take place within
primary health care facilities, which are much more accessible
to the patient population. During treatment, patients should
be continuously monitored. Prior to treatment initiation and
biweekly, patients should receive a haemogram and tests of
renal and hepatic function. Women of childbearing age should
undergo a pregnancy test before initiation, and use contraception during treatment. Management of adverse events
depends on their type and severity. Strategies for some of
the main AEs for benznidazole are suggested in recent guidelines [15], and may involve temporary reduction of daily dose
or temporary suspension of treatment until AEs resolve. If the
patient is near the end of treatment, discontinuation may be
the best option. According to the Argentinian guidelines,
> 30 days is sufficient to consider treatment complete [16].

5.3. Benznidazole during pregnancy and breastfeeding
BZN is traditionally contraindicated in pregnancy because data
that support its safety in the fetus are lacking [112].
Nevertheless, when the clinical picture of the patient is severe,
and given the known lower risks of fetal toxicity in the second
and third trimesters of pregnancy [113], treatment has been
administered on a compassionate basis. There are some case
reports in which it was necessary to prescribe treatment with
BZN during pregnancy due to the risk to the mother’s life in
the acute phase after vector/oral transmission [114,115] or
reactivation of chronic infection for a patient with AIDS [72].
All these cases showed a benefit for the mothers with a good
response to the treatment; no congenital infection was
detected in the children born, and no sequelae were described
in the children during follow-up.
A prospective study analyzed BZN concentrations in blood
samples and breastmilk from 12 lactating women receiving
treatment for CD [116]. Median observed breastmilk BZN concentrations were low; the expected exposure to BZN of
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Table 3. Global landscape of benznidazole registration, June 2018.
Country
Argentina
Bolivia
Brazil
Chile
El Salvador
Guatemala
Honduras
Mexico
Paraguay
United States

Presentation tablets
12.5 mg; 50 mg; 100 mg
50 mg; 100 mg
100 mg
50 mg; 100 mg
100 mg
50 mg; 100 mg
50 mg; 100 mg
50 mg; 100 mg
50 mg; 100 mg
12.5 mg; 100 mg

BZN registered
ELEA
ELEA
LAFEPE
ELEA
ELEA
ELEA
ELEA
ELEA
ELEA
CHEMO RESEARCH, S.L.

Note: Spain, Italy, Switzerland, Australia, and Canada are also authorized to
distribute the drug.

breastfeeding infants from mothers receiving BZN treatment
was estimated at 12% of the mother’s per kg dose, which is
considered safe. The researchers concluded mothers’ treatment with BZN should not contraindicate breastfeeding in
cases where treatment cannot be postponed.

6. Regulatory affairs
Table 3 lists countries where BZN is registered. Recently (2017),
the drug was registered in Mexico and the United States, the
countries with the third and sixth highest global burdens,
respectively. BZN is also on the WHO’s list of essential medicines. The Pan American Health Organization, through its
strategic fund, purchases BZN and resells it to countries
where it is not registered. In these countries, the BZN supply
is managed by ministries of health.
In the United States, BZN was previously only available
through the Centers for Disease Control. Physicians were
required to submit a special investigational protocol in order
to receive a supply of BZN for each patient. In 2017, the FDA
approved registration of benznidazole by Chemo Research (a
subsidiary of Insud Pharma). The U.S. product is available
through a central distributor (for more information see:
http://www.benznidazoletablets.com/en).
However, registration alone is insufficient to assure
patient access to BZN. Despite the proven benefits of etiological treatment of CD, health systems have struggled to
make the drug available to patients. In the United States
and other settings, fewer than 1% of expected CD cases
have received treatment [19,27,117]. Although 1,908 cases
of CD have been identified through testing of U.S. blood
donors from 2007 to 2013, only 422 courses of medication
were solicited from the CDC, enough to cover just 22% of
these cases [19].
Several barriers have prevented patients in need from
accessing BZN. Both patient and provider awareness of CD is
low [18,118], which keeps down the demand for diagnosis.
Furthermore, many providers still operate under the assumption that CD should not be treated in the chronic phase,
despite the fact that there is now a consensus in international
organizations and national guidelines that most adults with
chronic CD should be offered treatment. In addition, CD disproportionately impacts socioeconomically vulnerable
patients who have low access to healthcare.

In the United States and Europe, the majority of CD
patients are Latin American immigrants, who may be
excluded from health insurance coverage or be apprehensive about utilizing health services. A recent study indicated
that transportation, lack of providers, low provider awareness, language barriers, and immigration status were potential barriers encountered by U.S. patients with CD [20].
There is no routine screening for CD in the United States
outside of blood and organ donations. Increasing access to
BZN will require development of broad provider and patient
education initiatives, and incorporation of treatment into
healthcare services that are accessible to the population at
risk.

7. Conclusion
BZN is a small molecule with a nitroheterocyclic structure that
shows broad-spectrum trypanocidal activity against T. cruzi
strains from different DTUs. It exhibits a time- and concentration-dependent effect against intra- and extracellular forms of
T. cruzi. Its mechanism of action involves activation of the
parent molecule by trypanosomal type I nitroreductases and
generation of reactive metabolites.
BZN produces a clear trypanocidal effect in humans and plays
an essential role in primary and secondary prevention. Although
treatment with BZN is associated with side effects in some
patients, it has a good adherence rate and tolerability, especially
when treatment is carefully monitored. Because of the challenges involved in confirming a cure for CD, BZN’s benefit is
more readily demonstrated during the acute phase, and for
children, adolescents, and young adults with chronic indeterminate CD. Nonetheless, several observational studies suggest that
BZN prevents morbimortality in adults. The BENEFIT trial was not
able to show a similar effect in a sample of older adults who had
already developed heart disease from CD. Therefore, every effort
should be made to identify and treat patients early, before CD
progresses to an advanced chronic form.
Another important benefit of BZN treatment is primary prevention. When T. cruzi-infected women are treated with BZN,
congenital transmission is prevented in subsequent births. This
has tremendous public health importance since congenital
infection is a major transmission route. Consequently, treatment
of women of gestational age should be an integral part of
public health strategies. Finally, BZN plays a critical role in
reducing the burden of CD and increasing the number of
healthy, productive years of life of patients.

8. Expert commentary
Ongoing investigations aim to optimize BZN therapy by
adjusting the current standard regimen [73,80,83] or by combining BZN with new chemical entities [80–82]. These studies
are assessing alternatives to improve safety while improving
or at least maintaining the efficacy of BZN.
Infants and children respond well to BZN treatment, with
relatively few, mostly mild adverse events. Treatment early in
life produces consistently negative parasitological responses
on qPCR, even years after treatment, and often causes reversion to negative serology. For insight on the role of
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treatment in prevention of chronic complications such as
heart disease, studies of treated children with 3 or 4 decades
of follow-up will be illustrative. The current absence of this
type of long-term follow-up data has forced researchers to
base treatment decisions and recommendations on surrogate markers such as antibody titers and parasitological
clearance measured by qPCR, which may not have adequate
sensitivity and specificity. Nevertheless, in pediatric studies,
all the surrogate markers support BZN’s effectiveness.
Additionally, monitoring of treated females who bore children later in life has not uncovered a single case of congenital transmission, which strongly supports the value of early
treatment of CD.
Public health programs for CD must employ a two-pronged
strategy, on the one hand interrupting transmission to prevent
occurrence of new cases (these measures are cost-effective),
while on the other hand providing timely diagnosis and treatment to infected individuals to prevent clinical evolution of
the disease, reduce morbidity, and maximize healthy years of
life. When these actions are implemented in a comprehensive,
integrated manner, it will be possible to interrupt transmission
of T. cruzi in a large territory and eliminate CD as a public
health problem, with a dramatic reduction in the burden of
the disease [14].

9. Five-year view
Substantial progress has been made in the past decade, improving our understanding of BZN’s efficacy and safety. BZN is likely
to remain the first-line treatment for CD in the coming years.
Ongoing studies (BENDITA and MULTIBENZ) will provide further
insight within the next five years, helping to determine whether
intermittent dosage schemes, shorter regimens, and/or lower
doses are capable of sustaining the efficacy of the standard
regimen while improving the side effect profile. Moreover, the
results of the BENDITA trial will indicate whether BZN and E1224
combination therapy can yield superior safety and/or efficacy
than the standard regimen. Meanwhile, other compounds in the
nitroheterocyclic class continue to be evaluated. Fexinidazole,
recently proven effective against human African trypanosomiasis
[119], could be the next promising candidate for CD [120–122].
Clinical research continues to be hampered by the lack of a
reliable measure of cure. New biomarkers with improved sensitivity to demonstrate failure and success in a timely fashion
are needed. Identification of new biomarkers that more accurately measure efficacy could revolutionize clinical research
and practice, and some initiatives are ongoing [123].
The 2017 registration of benznidazole in Mexico and the
United States removes regulatory barriers in two high-burden
countries. Nonetheless, much work is needed to improve access
for patients. Persistently low awareness among providers of
current CD treatment guidelines, the absence of a gold standard
for diagnosis, and a lack of widespread screening and treatment
at the primary care level are key barriers. Providers capable of
offering treatment are still too few, and often located too far
from areas where patients live. Most importantly, CD predominantly impacts socioeconomically vulnerable groups who face
significant challenges in accessing healthcare; these challenges
are further magnified for immigrants in Europe and the United
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States who face legal, social, and linguistic barriers. Incorporation
of etiological treatment with BZN and NFX into the primary
health care system is still in its infancy, but successful models in
Bolivia, Argentina, and elsewhere provide a template other programs can follow [124–126].

Key issues
● BZN is a prodrug that requires activation by trypanosomal
type I nitroreductases (NTRI). The group of reactive metabolites produced during the activation step is toxic, promoting a
fast and concentration-dependent kill-off of the parasites.
● In vitro, BZN has broad-spectrum trypanocidal activity
against intra- and extracellular forms of T. cruzi strains
belonging to discrete distinct typing units (DTUs). In several
animal models, BZN improves survival, reduces parasite
load in blood and key reservoir tissues, decreases antibody
response to T. cruzi, and may prevent the development of
severe clinical features of the disease.
● BZN has a clear trypanocidal effect, which is more evident
the more recent the infection. Furthermore, there is growing evidence from observational studies that etiological
treatment with BZN reduces morbimortality when administered to adults with chronic CD.
● Clinical research with new treatment schemes evaluating
alternative doses and durations as well as combination
therapies is ongoing, aiming primarily at improving or
maintaining efficacy while bolstering safety.
● There is absolute consensus that treatment with BZN and
NFX should be offered within primary healthcare.
Treatment adherence and safety is greatly enhanced when
healthcare personnel engage in systematic monitoring of
side effects.
● BZN has been approved in nine countries in the Americas
for the treatment of CD, including the United States and
Mexico in August 2017.
● Etiological treatment with BZN is recommended for acute
and congenital cases, reactivations in immunocompromised
patients, and children in the early chronic phase. Treatment
should also be offered to adults with chronic infection
because of evidence that it reduces morbimortality, and is
sometimes considered as a prophylactic measure in
patients about to undergo immunosuppressive therapy.
Treatment appears to be more effective when administered
before the onset of serious cardiac complications (Kuschnir
class II or III).
● There is a consensus that patient care involving antitrypanosomal treatment be integrated into primary prevention
programs, particularly because of its demonstrated ability
to eliminate congenital transmission. Preventing new cases
is key to eliminating CD as a public health problem.
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